Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma

Download guidance (PDF)

7 Related NICE guidance

Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma. NICE technology appraisal guidance 169 (2009).
Percutaneous radiofrequency ablation of renal cancer. NICE interventional procedure guidance 91 (2004). [Replaced by NICE interventional procedure guidance 353 (2010)]
Improving outcomes in urological cancers. NICE cancer service guidance (2002).